A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.

NCT05005468 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

61

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Camrelizumab
DRUG: Famitinib

Sponsor

Shanghai Chest Hospital